


Strengthening Program for Pharmaceutical Startup Ecosystem

Japan Agency for Medical Research and Development (AMED)

AMED is a Japanese government agency that plays a key role in promoting and subsidizing medical research and development in Japan.

AMED's **Strengthening Program for Pharmaceutical Startup Ecosystem** is specifically designed to address the challenges pharmaceutical startups face in securing substantial development funding, especially during critical stages such as non-clinical/pre-clinical studies, Phase I, Phase II, and exploratory clinical trials.



* **Registration** ----- Registration of VCs with track records of investment and support, etc. in the drug discovery field

** **Hands-on Support** ----- Support according to the growth stage of Pharmaceutical Startups from the perspectives on management, development and technology, and regulatory affairs

Key requirements for bio-venture startups

- ❑ Japanese office and at least 3 people
(Representative, Head of R&D, Accounting and Administrative Officer)
- ✕ AMED subsidies become unavailable immediately upon IPO or M&A completion
- ❑ Proof of Concept (POC) to finish by Sep. 2031
- ❑ Confirmed funding of >1B yen from registered VC

Source:

- The official website of AMED (<https://www.amed.go.jp/en/program/list/19/02/005.html>)
- "Strengthening Program for Pharmaceutical Startup Ecosystem (September 2024)"
<https://www.amed.go.jp/content/000131485.pdf>

Navigate Japan market entry and support AMED program applications

As Japan's pioneering and leading Contract Research Organization (CRO), CMIC Group provides comprehensive support to international startups seeking to initiate drug development in Japan through AMED subsidies.

As of June 2025, CMIC has supported 7 applications including those for global startup companies.



Development strategy consulting

We provide strategic guidance based on our vast expertise and experience on Japan's regulatory framework



End-to-end solution partner in Japan

CMIC Group offers solutions from pre-clinical, to clinical, to commercialization seamlessly



AMED program application support

Our experts support startups prepare competitive applications

- ✓ **Build robust development strategy in Japan aligning with global strategy**
- ✓ **Create optimal product positioning through comprehensive understanding of the Japan market**
- ✓ **Create a case to demonstrate a strong commitment to the Japan market**



Established network of Key Opinion Leaders (KOLs)

We have a strong relationship with Japanese KOLs in various therapeutic areas

CMIC Group

Email: information@cmic.co.jp

en.cmicgroup.com

June 2025

©2025 CMIC HOLDINGS Co., Ltd. All Rights Reserved